<html><head>
<meta http-equiv="Content-Type" content="text/html; charset=Windows-1252"></head><body style="word-wrap: break-word; -webkit-nbsp-mode: space; -webkit-line-break: after-white-space; color: rgb(0, 0, 0); font-size: 14px; font-family: Calibri, sans-serif; "><div><br></div><span id="OLK_SRC_BODY_SECTION"><div xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><div lang="EN-US" link="blue" vlink="purple"><div class="WordSection1"><p class="MsoNormal" align="center" style="text-align:center"><img width="497" height="62" id="Picture_x0020_1" src="cid:image001.jpg@01D22316.BA9204B0" alt="cid:image001.jpg@01D2208E.B9778B70"><o:p></o:p></p><p class="MsoNormal" align="center" style="text-align:center"><b><span style="font-size:12.0pt;color:black">Seminar<br></span></b><b><span style="font-size:14.0pt">Imaging and Therapy Directed at Cancer Stroma Cells<o:p></o:p></span></b></p><p class="MsoNormal" align="center" style="mso-margin-top-alt:auto;mso-margin-bottom-alt:auto;text-align:center"><b><span style="font-size:11.5pt;color:red">Friday, <u>October 14</u>, 2016<br>
SEC 204: 12-1PM<o:p></o:p></span></b></p><p class="MsoNormal" align="center" style="text-align:center"><b><span style="font-size:11.5pt">Speaker: Dr. Chun Li<o:p></o:p></span></b></p><p class="MsoNormal" align="center" style="text-align:center"><b><span style="font-size:11.5pt">Professor<o:p></o:p></span></b></p><p class="MsoNormal" align="center" style="text-align:center"><b><span style="font-size:11.5pt">Departments of Cancer Systems Imaging, The University of Texas
<o:p></o:p></span></b></p><p class="MsoNormal" align="center" style="text-align:center"><b><span style="font-size:11.5pt">M. D. Anderson Cancer Center, Houston, Texas<o:p></o:p></span></b></p><p class="MsoNormal" align="center" style="text-align:center"><b><span style="font-size:11.5pt"><o:p> </o:p></span></b></p><p class="Default"><b><span style="font-size:11.5pt">Abstract:</span></b><span style="font-size:11.5pt"></span><o:p></o:p></p><p class="MsoNormal">Tumor stroma is characterized by the presence of a large number of cancer associated fibroblasts, macrophages, endothelial cells, and other immune cells. These cells are often present in aberrantly high numbers in tumor microenvironment
that are distinctly different from normal cells. Targeting stroma cells proves a unique opportunity for cancer imaging and therapy. We have exploited the use of nanoparticles and imaging probes directed at cancer associated fibroblasts and macrophages for
imaging therapy-induced cell death, assessing host response to tumor progression and suppression, and potentiation of conventional chemoradiotherapy. These work will be presented and discussed in the context of pancreatic cancer and ovarian cancer, and inflammatory
diseases in my talk.<span style="font-size:11.5pt"><o:p></o:p></span></p><p class="MsoNormal"><span style="font-size:11.5pt"><o:p> </o:p></span></p><p class="Default"><b><span style="font-size:11.5pt">Bio: <o:p></o:p></span></b></p><p class="MsoNormal"><b><span style="font-size:11.5pt;color:black">Chun Li, Ph.D.</span></b><span style="font-size:11.5pt;color:black"> is a professor in the Department of Cancer Systems Imaging at The University of Texas M. D. Anderson Cancer Center. Dr. Li
earned his doctorate in chemistry at Rutgers-The State University of New Jersey. His undergraduate degree was obtained from Peking University, Beijing, China. Research in Dr. Li’s laboratory is primarily focused on two areas: 1) Develop targeted imaging probes
for noninvasive characterization of molecular events associated with tumor progression and regression. Multiple imaging modalities, including PET, SPETC, MRI and optical imaging are used to acquire complementary data with increased sensitivity and selectivity
for early tumor detection, tumor-marker profiling and the monitoring of early treatment responses. 2) Develop novel drug-delivery systems for selective delivery of diagnostic and therapeutic agents to the disease sites. Nanometric drug carriers are designed
for selective delivery of anticancer agents to the tumor to maximize their therapeutic efficacy and minimize their toxic side effects to normal tissue. The long-term goal of Dr. Li’s laboratory is to apply the “seek and treat” strategy in the development of
targeted imaging/ therapeutic (theranostic) agents that will eventually be translated to the clinic to improve the management of cancer through early tumor detection and individualized therapy. A polymer-drug conjugate (PG-TXL) originated from his laboratory
has advanced into clinical phase III trials studies. Dr. Li has more than 140 papers published in peer-reviewed journals, 28 patents (4 of which have been licensed), 1 edited book, and 14 book chapters.<o:p></o:p></span></p></div></div></div></span><style><!--
/* Font Definitions */
@font-face
{font-family:SimSun;
panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Tahoma;
panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
{font-family:"\@SimSun";
panose-1:2 1 6 0 3 1 1 1 1 1;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
{mso-style-priority:99;
mso-style-link:"Balloon Text Char";
margin:0in;
margin-bottom:.0001pt;
font-size:8.0pt;
font-family:"Tahoma","sans-serif";}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri","sans-serif";
color:windowtext;}
p.Default, li.Default, div.Default
{mso-style-name:Default;
margin:0in;
margin-bottom:.0001pt;
text-autospace:none;
font-size:12.0pt;
font-family:"Arial","sans-serif";
color:black;}
span.BalloonTextChar
{mso-style-name:"Balloon Text Char";
mso-style-priority:99;
mso-style-link:"Balloon Text";
font-family:"Tahoma","sans-serif";}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri","sans-serif";}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style></body></html>